



STROKE

TBI

DEMENTIA

ECOMPASS confirms CARS results

Cerebrolysin significantly improves motor functions

Pharmacological effect on motor function recovery of **STROKE** patients

*Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke
Chang et al. BMC Neurology (2016) 16:31*

ECOMPASS results - Cerebrolysin in patients after STROKE

- Improvement of motor functions
- Recovery of motor-neuron network
- Significant recovery with Cerebrolysin treatment start 8 days post stroke

Cerebrolysin[®]

Reconnecting Neurons.
Empowering for Life.

Cerebrolysin significantly improves motor function by 200%

Regain upper limb functionality for increased independence and quality of life




Figure 1: Primary Outcome of ECOMPASS, FMA* score in patients

It's never too late to start with Cerebrolysin!

- Significant recovery with Cerebrolysin treatment start 8 days post stroke
- Increases quality of life
- Better arm mobility for increased independence
- Facilitates activities of daily living



full article

Titel Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. A randomized, placebo-controlled, double-blind, multicenter trial.
ECOMPASS = Effects of Cerebrolysin on motor recovery in patients with subacute stroke

Patients 70 randomized patients (35 Cerebrolysin vs. 35 placebo)

Treatment Beginning at day 8 after stroke onset
 Cerebrolysin group = Cerebrolysin + standard rehabilitation program
 Placebo group = Saline + standard rehabilitation program
30ml/day for 21 days
 Primary endpoint = FMA* score on day 21, 60 and 90

* FMA = Fugl Meyer Assessment

ABBREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, pre-clinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

Copyright © 2016 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria